We are happy to welcome the next Molecular Devices’ Imaging User Meeting here in our laboratories in Lille! We hope it will be maintained in person. For sure it will be a pleasure to participate in the great event, after the last one which took place in Leiden in 2020. Read more…
Have you missed our last webinar with Molecular Devices about 3D oncology models? In April, our project leader Elodie was talking about how to establish and image physiologically relevant 3D cancer in vitro models, using BIOMIMESYS Oncology as a surrogate for the tumoral extracellular matrix. Our product BIOMIMESYS® Oncology matrix Read more…
We will give a presentation next week (on Tuesday, 10th of March 2020) at the High-Content Cellular Imaging User meeting organized by our partner Molecular Devices, which will take place in Leiden (Netherlands). It is a great pleasure for us to attend the meeting, and to talk about the applications, Read more…
Nathalie and Elodie will be present in Marseille for BioFit event next week! Indeed, HCS Pharma has a booth in Clubster NSL’s pavilion (number I20). Just stop by 🙂 It will be a pleasure to talk to you about the innovative 3D cell culture matrix BIOMIMESYS® and our related services Read more…
We will be present this week and next week in Rotterdam, to talk about 3D cell culture and the importance of the microenvironnement in the relevance of in vitro models. As you known, to mimic human tissues, several parameters need to be taken into account: the target cells, nutrient intake Read more…
Quantifying DNA damage is mandatory to assess potential adverse effects of candidate, drugs, molecules or extracts developed in dermo-cosmetic industry. Different assays can be performed to detect primary DNA damages, such as γH2AX or the single cell gel electrophoresis also known as the comet assay.